Novel polypeptide and anti-hiv agent containing the same
CA 2421183 C · Owner: Takeda Chemical Industries, Ltd. · Inventors: Fujii, Nobutaka
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a polypeptide represented by the formula:, A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit-Cys-A7 (I) (wherein A1 represents a hydrogen atom or an arginine lysine, ornithine, citrulline, alanine residue etc.; A2 , represents an aromatic amino acid residue; A3 A4 and A6 , represent an arginine, lysine ornithine, citrulline or , alanine residue A5 represents a tyrosine, phenylalanine alanine, naphthylalanine or citrulline residue; A7 represents a lysine or arginine residue in which a carboxyl group may be amidated; X represents a D-ornithyl-proline prolyl-D-ornithine, D-lysyl-proline residue etc.; provided , that either of A1, A3 A4, A5, A6 and A7 is an alanine , …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 5, 2001 and granted June 16, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 5, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 5, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.